Thus, PKM2’s role in tumor metabolism and progression may involve distinct molecular pathways, such as those related to glycolysis or alternative metabolic reprogramming mechanisms, warranting further investigation into its potential as a therapeutic target in both IDH-mutant and IDH-wild type tumors. This evidence concerns the gene IDH1 and neoplasm.